Safety and efficacy of sonodynamic therapy combined with Stupp regimen in controlling postoperative residual lesions of glioblastoma: A prospective pilot phase I study.
Photodiagnosis Photodyn TherSep 18, 2026 (epub)
Long Wang, Jiayin Ding, Xiaohao Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective Phase I trial evaluated the safety and preliminary efficacy of sonodynamic therapy (SDT) combined with the Stupp regimen in 18 newly diagnosed glioblastoma patients with postoperative residual lesions. Over a median follow-up of 26.23 months, the study found no treatment-related deaths, with a median overall survival of 19.00 months and a 12-month overall survival rate of 88.9%.
Key findings
- No treatment-related deaths or grade 4/5 toxicities were reported.
- Median overall survival was 19.00 months with a 12-month OS rate of 88.9%.
- The overall response rate was 66.7%, with a disease control rate of 100%.
- In the maintenance subgroup, SDT + TMZ showed an ORR of 88.9% compared to 44.4% for TMZ alone.
Why it matters
The study suggests that combining sonodynamic therapy with standard chemoradiotherapy may enhance treatment outcomes for glioblastoma patients with residual disease, potentially improving overall survival and response rates.